Caladrius Bioscience To Start Testing Its CD34+ Cell Therapy in Diabetic Kidney Disease
Novartis's Iptacopan Aces Mid-Stage Kidney Disease Trial
Travere Therapeutics' Sparsentan Program Submission Pushed to 2022; FDA Requires More Data
Calliditas Therapeutics Files US Application For Nefecon In Kidney Disease